WESTLAKE VILLAGE, CA
Zoryve cream cleared for pediatric plaque psoriasis
- Sponsor
- Arcutis Biotherapeutics $ARQT
- Drug
- Zoryve · roflumilast
- Indication
- Plaque psoriasis in patients aged 2 and older (topical, cream 0.3%)
FDA approved Arcutis's Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children aged 2 and older, expanding the label from its prior adult and adolescent indications.
Read original at drugs.com ↗Drug Watch — recent news on Zoryve
- META_TITLE_QUOTE - Yahoo Finance
- US FDA Accepts sNDA for Roflumilast Cream in Infants With AD: What This Could Mean for Families Featuring Dr. Lawrence F. Eichenfield - The Dermatology Digest
- The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following FDA Acceptance Of Infant ZORYVE sNDA - webull.com
- FDA Expands Use of Zoryve to Include Young Children With Plaque Psoriasis - Clinical Pain Advisor
- The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following FDA Acceptance Of Infant ZORYVE sNDA - simplywall.st
Sponsor Watch — recent news on Arcutis Biotherapeutics
- AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
- How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story
- AstraZeneca (LSE:AZN) Wins EU Approval For Etcamah In Advanced Breast Cancer
- EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
- J&J's Innovative Medicine Unit Proves Its Resilience in Q2